Dual PI3K-mTOR inhibitor gedatolisib has been granted a fast-track designation by the FDA as a potential therapeutic option in patients with HR+/HER2- metastatic BC who experienced disease progression on CDK4/6 therapy [26]. Here, ERBB2 is linked to breast cancer.